Abstract
Marijuana has been known to decrease intraocular pressure in humans since the early 1970s. However, its broad side effect profile, short half-life, and limited corneal penetration have prevented its development into a commercial ocular anti-hypertensive. Our paper aims to evaluate the latest research on the role of cannabinoids in the treatment of glaucoma and whether or not there is any progress in overcoming the above limitations. Several techniques for retaining the therapeutic effect and minimizing or eliminating the side effects of Δ-9-tetrahydrocannabinol are being investigated, but these are still in the early stages. Much work still needs to be done before a cannabinoid-based ocular antihypertensive is commercially available.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
